Baseline characteristics of the study cohort (n = 49)
| Characteristic . | Patients treated with SL-401 as the first line (n = 12) . | Patients treated with CTx as the first line (n = 21)* . | Patients not treated or received other regimens (n = 16)† . | All patients (N = 49) . |
|---|---|---|---|---|
| Age at diagnosis, median (range), y | 73.6 (32.0-79.8) | 61.1 (36.6-83.9) | 77.7 (40.6-91.4) | 71.4 (32.0-91.4) |
| Time period of diagnosis, n (%) | ||||
| 2001-2005 | 0 (0) | 3 (14) | 1 (6) | 4 (8) |
| 2006-2010 | 0 (0) | 6 (29) | 5 (31) | 11 (22) |
| 2011-2015 | 2 (17) | 10 (48) | 6 (38) | 18 (37) |
| 2016-2019 | 10 (83) | 2 (10) | 4 (2) | 16 (33) |
| Sex, n (%) | ||||
| Male | 11 (92) | 18 (86) | (69) | 40 (82) |
| Female | 1 (8) | 3 (14) | 5 (31) | 9 (18) |
| Prior hematologic malignancies, n (%) | ||||
| MDS | 1 (8) | 0 (0) | 1 (6) | 2 (4) |
| CMML | 0 (0) | 0 (0) | 1 (6) | 2 (4) |
| ET | 0 (0) | 1 (5) | 0 (0) | 1 (2) |
| Concurrent hematologic malignancies, n (%) | ||||
| MDS | 1 (8) | 1 (5) | 1 (6) | 3 (6) |
| AML | 0 (0) | 0 (0) | 1 (6) | 1 (2) |
| CMML | 2 (16) | 1 (5) | 2 (13) | 5 (10) |
| ET | 0 (0) | 1 (5) | 0 (0) | 1 (2) |
| PTCL | 0 (0) | 1 (5) | 0 (0) | 1 (2) |
| Disease involvement at diagnosis, n (%) | ||||
| Skin | 10 (83) | 17 (81) | 15 (94) | 42 (86) |
| BM | 7 (58) | 16 (76) | 9 (56) | 32 (65) |
| LN | 3 (25) | 8 (38) | 2 (13) | 13 (27) |
| Nasopharynx | 1 (8) | 1 (5) | 0 (0) | 2 (4) |
| Splenomegaly | 3 (25) | 2 (10) | 2 (13) | 7 (14) |
| NGS assessments,‡ n (%) | 9 (75) | 3 (14) | 2 (13) | 14 (29) |
| TET2 | 8 (67) | 2 (10) | 2 (13) | 12 (86) |
| ASXL1 | 3 (25) | 3 (14) | 1 (6) | 7 (50) |
| NRAS | 1 (8) | 0 (0) | 1 (6) | 2 (14) |
| KRAS | 0 (0) | 1 (5) | 0 (0) | 1 (7) |
| SRSF2 | 2 (16) | 0 (0) | 0 (0) | 2 (14) |
| SF3B1 | 2 (16) | 0 (0) | 0 (0) | 2 (14) |
| ZRSR2 | 0 (0) | 2 (10) | 0 (0) | 2 (14) |
| NOTCH1 | 2 (16) | 0 (0) | 0 (0) | 2 (14) |
| EZH2 | 1 (8) | 1 (5) | 0 (0) | 2 (14) |
| PFH6 | 0 (0) | 0 (0) | 1 (6) | 1 (7) |
| NGS not performed, n (%) | 3 (25) | 18 (86) | 14 (88) | 35 (71) |
| First-line treatment, n (%) | ||||
| Chemotherapy | 0 (0) | 21 (100) | 3 (19) | 24 (49) |
| CHOP-based regimens | 0 (0) | 10 (48) | 0 (0) | 10 (20) |
| Hyper-CVAD | 0 (0) | 11 (52) | 0 (0) | 11 (22) |
| CLAG | 0 (0) | 0 (0) | 1 (6) | 1 (2) |
| Methotrexate/pralatrexate | 0 (0) | 0 (0) | 2 (13) | 2 (4) |
| SL-401 | 12 (100) | 0 (0) | 0 (0) | 12 (24) |
| Radiation | 0 (0) | 0 (0) | 5 (31) | 5 (10) |
| Transplant, n (%) | ||||
| Autologous stem cell transplant | 0 (0) | 4 (19) | 0 (0) | 10 (20) |
| Allogeneic stem cell transplant | 3 (25) | 7 (33) | 0 (0) | 4 (8) |
| Alive at last follow-up, n (%) | ||||
| No | 5 (42) | 4 (10) | 3 (19) | 12 (24) |
| Yes | 7 (58) | 17 (90) | 13 (81) | 37 (76) |
| Characteristic . | Patients treated with SL-401 as the first line (n = 12) . | Patients treated with CTx as the first line (n = 21)* . | Patients not treated or received other regimens (n = 16)† . | All patients (N = 49) . |
|---|---|---|---|---|
| Age at diagnosis, median (range), y | 73.6 (32.0-79.8) | 61.1 (36.6-83.9) | 77.7 (40.6-91.4) | 71.4 (32.0-91.4) |
| Time period of diagnosis, n (%) | ||||
| 2001-2005 | 0 (0) | 3 (14) | 1 (6) | 4 (8) |
| 2006-2010 | 0 (0) | 6 (29) | 5 (31) | 11 (22) |
| 2011-2015 | 2 (17) | 10 (48) | 6 (38) | 18 (37) |
| 2016-2019 | 10 (83) | 2 (10) | 4 (2) | 16 (33) |
| Sex, n (%) | ||||
| Male | 11 (92) | 18 (86) | (69) | 40 (82) |
| Female | 1 (8) | 3 (14) | 5 (31) | 9 (18) |
| Prior hematologic malignancies, n (%) | ||||
| MDS | 1 (8) | 0 (0) | 1 (6) | 2 (4) |
| CMML | 0 (0) | 0 (0) | 1 (6) | 2 (4) |
| ET | 0 (0) | 1 (5) | 0 (0) | 1 (2) |
| Concurrent hematologic malignancies, n (%) | ||||
| MDS | 1 (8) | 1 (5) | 1 (6) | 3 (6) |
| AML | 0 (0) | 0 (0) | 1 (6) | 1 (2) |
| CMML | 2 (16) | 1 (5) | 2 (13) | 5 (10) |
| ET | 0 (0) | 1 (5) | 0 (0) | 1 (2) |
| PTCL | 0 (0) | 1 (5) | 0 (0) | 1 (2) |
| Disease involvement at diagnosis, n (%) | ||||
| Skin | 10 (83) | 17 (81) | 15 (94) | 42 (86) |
| BM | 7 (58) | 16 (76) | 9 (56) | 32 (65) |
| LN | 3 (25) | 8 (38) | 2 (13) | 13 (27) |
| Nasopharynx | 1 (8) | 1 (5) | 0 (0) | 2 (4) |
| Splenomegaly | 3 (25) | 2 (10) | 2 (13) | 7 (14) |
| NGS assessments,‡ n (%) | 9 (75) | 3 (14) | 2 (13) | 14 (29) |
| TET2 | 8 (67) | 2 (10) | 2 (13) | 12 (86) |
| ASXL1 | 3 (25) | 3 (14) | 1 (6) | 7 (50) |
| NRAS | 1 (8) | 0 (0) | 1 (6) | 2 (14) |
| KRAS | 0 (0) | 1 (5) | 0 (0) | 1 (7) |
| SRSF2 | 2 (16) | 0 (0) | 0 (0) | 2 (14) |
| SF3B1 | 2 (16) | 0 (0) | 0 (0) | 2 (14) |
| ZRSR2 | 0 (0) | 2 (10) | 0 (0) | 2 (14) |
| NOTCH1 | 2 (16) | 0 (0) | 0 (0) | 2 (14) |
| EZH2 | 1 (8) | 1 (5) | 0 (0) | 2 (14) |
| PFH6 | 0 (0) | 0 (0) | 1 (6) | 1 (7) |
| NGS not performed, n (%) | 3 (25) | 18 (86) | 14 (88) | 35 (71) |
| First-line treatment, n (%) | ||||
| Chemotherapy | 0 (0) | 21 (100) | 3 (19) | 24 (49) |
| CHOP-based regimens | 0 (0) | 10 (48) | 0 (0) | 10 (20) |
| Hyper-CVAD | 0 (0) | 11 (52) | 0 (0) | 11 (22) |
| CLAG | 0 (0) | 0 (0) | 1 (6) | 1 (2) |
| Methotrexate/pralatrexate | 0 (0) | 0 (0) | 2 (13) | 2 (4) |
| SL-401 | 12 (100) | 0 (0) | 0 (0) | 12 (24) |
| Radiation | 0 (0) | 0 (0) | 5 (31) | 5 (10) |
| Transplant, n (%) | ||||
| Autologous stem cell transplant | 0 (0) | 4 (19) | 0 (0) | 10 (20) |
| Allogeneic stem cell transplant | 3 (25) | 7 (33) | 0 (0) | 4 (8) |
| Alive at last follow-up, n (%) | ||||
| No | 5 (42) | 4 (10) | 3 (19) | 12 (24) |
| Yes | 7 (58) | 17 (90) | 13 (81) | 37 (76) |
CLAG, cladribine, cytarabine, granulocyte colony stimulating factor; CTx, chemotherapy; PTCL, peripheral T-cell lymphoma.
CTx in this group includes CHOP-based regimens and hyper-CVAD. CHOP-based regimens include CHOP, CNOP, and EPOCH.
Other regimens in this group include AML induction regimen, methotrexate, pralatrexate, and radiation.
NGS analyses were performed using BM samples at the diagnosis of BPDCN.